Business
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
ZUG, Switzerland, December 04, 2025--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook.
About this update from Galderma Group Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/56df70dc18f95534f44db63b75e0c7c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NvteKjqKoDSbaQRD8Nh.Xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/56df70dc18f95534f44db63b75e0c7c0","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XJc3j_gjNMC0lSToQeo3Zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/56df70dc18f95534f44db63b75e0c7c0","width":823,"height":209}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"‘BBB’ long-term issuer credit rating from S&P Global Ratings","length":64,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Positive outlook, reflecting expected profitability improvement, ramp up of Nemluvio, and continued deleveraging and balance sheet improvement","length":142,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Recognition of Galderma’s science-based dermatology portfolio and global operations","length":83,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":289,"olType":false},{"type":"text","content":"ZUG, Switzerland, December 04, 2025--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook.","length":269,"tagName":"p"},{"type":"text","content":"The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. S&P notes the company’s well-established brand portfolio, global footprint, including an expanding presence in emerging markets, and continued investment in science-based innovation.","length":356,"tagName":"p"},{"type":"text","content":"S&P highlights momentum from recent launches, including Nemluvio® (nemolizumab), alongside improving profitability and expanding free operating cash flow. The agency also notes Galderma’s disciplined financial policy, supporting expectations of continued deleveraging over t...